Loading...

LUNG CANCER TARGETED THERAPY PANEL

image not found

NABL Cap Accredited 
The Lung Cancer Targeted Therapy Panel is an advanced molecular test designed to detect actionable genetic mutations in lung cancer that can guide personalized therapy. Using patient tissue or blood samples, Metropolis Healthcare employs next-generation sequencing (NGS) and other sensitive techniques to identify mutations in key oncogenes and tumor suppressor genes. This panel helps clinicians select targeted therapies, predict treatment response, and monitor disease progression for improved patient outcom

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 21,000.00

Sample Type: Slide,Tissue

Fasting Not Required


Notes:L0133

Frequently Asked Questions (FAQ's):

What does the Lung Cancer Targeted Therapy Panel include?
It analyzes multiple genes known to influence lung cancer growth and responsiveness to targeted treatments.

Who should take this test?
Patients diagnosed with lung cancer or those requiring guidance for targeted therapy options.

How is the sample collected?
Depending on clinical needs, a tissue biopsy or blood sample is used for molecular analysis.

Can this test guide personalized treatment?
Yes, it identifies actionable mutations that help oncologists choose the most effective targeted therapies.

How does Metropolis Healthcare perform this test?
Metropolis Healthcare uses next-generation sequencing and validated molecular techniques for precise mutation detection.

Is this test useful for monitoring treatment response?
Yes, serial testing can help track mutation status and disease progression.

Is fasting required for the test?
No fasting is necessary.

How long does it take to receive results from Metropolis Healthcare?
Results are typically available within 10–21 days, depending on the complexity of the panel.

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab